Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
Moderna battles Pfizer/Biontech to generate the first pivotal study data for a Covid-19 vaccine.
November 6 is the day that could make or break Biogen.
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
An attempt to abrogate the placebo response does not seem to have gone as planned.
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
As the company is punished for its failure to diversify, could it be forced into making an acquisition?
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
Approval of ALKS 3831 looks likely after Friday’s positive panel vote, but sales might disappoint.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.